Tenon OKd for New Indication to Augment Spinal Fusion

 Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, announced today that the U.S. Food and Drug Administration (FDA) has provided clearance of an expanded indication for the Catamaran® SI Joint Fusion System (the "Catamaran") for use in augmenting thoracolumbar fusion. With this approval, the Catamaran is now indicated to treat the SI joint as either a stand-alone treatment or to augment a spinal fusion.

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/tenon-medicalr-announces-fda-clearance-of-catamaranr-si-joint-fusion-1004697